Synlogic Shares Tumble 55% on Discontinued Trial, Halt to Op

By Ben Glickman Shares of Synlogic fell sharply after the company opted to cease operations after stopping a clinical trial. The stock was down 55% to $1.56...

Related Keywords

, Aoife Brennan , Ben Glickman , Chief Executive Aoife Brennan , Article Normal , Biotechnology Services , Pharmaceuticals , Healthcare Life Sciences , Biopharmaceuticals , Financial Performance , Share Price Movement Disruptions , New Products Services , Research Development , Corporate Industrial News , Products Services , New Product Service Testing , Content Types , Factiva Filters , C Amp Ampe Exclusion Filter , C Amp Ampe Industry News Filter , Synd , Synlogic , Sybx , Share Price Movement , Disruptions , New Products , Services , Research , Development , Corporate , Industrial News , Products , New Product , Service Testing , Healthcare , Life Sciences ,